# Hengrui Medicine
Latest news and articles about Hengrui Medicine
Total: 3 articles found
Monetizing the Pulse: China’s Hospital Data Gold Rush and the Erosion of Patient Privacy
China's public hospitals are increasingly selling patient datasets to pharmaceutical and AI companies under a state-led mandate to monetize 'data elements.' While this fuels medical innovation, it raises significant legal and ethical questions regarding patient privacy and the lack of specific informed consent for commercial data use.
Hengrui’s Oral GLP‑1/GIP Candidate Shows Promising 26‑Week Weight Loss in China — A Potential Game‑Changer for Obesity Care
Hengrui Medicine and Kailera Therapeutics reported positive top‑line results from a 166‑participant Phase II trial of ripubopetide, an oral GLP‑1/GIP dual agonist, showing up to 12.1% mean weight loss at 26 weeks and manageable vomiting rates. Hengrui will pursue Phase III studies in China while Kailera plans a global Phase II in 2026, though larger, longer trials are needed to confirm efficacy and safety.
China Stocks See Narrow, Resource-Led Rally as Growth Names Slip; ChiNext Ends Lower
Chinese markets closed mixed as resource and commodity stocks powered a narrow rally while growth and health-care sectors lagged. Heavy turnover and a broad list of declining stocks indicate the advance was concentrated in a small number of themes, raising volatility and regulatory risks for investors.